Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREYour new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESThe new Code of Practice, which became effective on January 1 of 2019, is the first revision since 2012. The IFPMA says the changes bring its Code into alignment with those of member associations including EFPIA and PhRMA.
In a release announcing the updated Code, the IFPMA specifically highlighted revised language in chapter 7.5 which tightens the restrictions on what are considered acceptable gifts. “Items in this section, where permissible, must never constitute an inducement to prescribe, recommend, purchase, supply, sell or administer a pharmaceutical product,” the IFPMA Code states.
The new language and clarifications build on the IFPMA’s 2012 guidelines that prohibited gifting for personal benefit. Now, in addition, pharmaceutical manufacturers must eschew giving “cultural courtesy gifts” and promotional aids, including ones given directly as well as through affiliated clinics and institutions.
Also included in the ban are prescription promotional aids. This includes — but is not limited to — sticky notes, mouse pads, calendars, bags, etc. Giving other similar non-monetary reminder products also is now prohibited by manufacturers. However, there is a carve-out in this stipulation that allows for promotion of over-the-counter medications if this is relevant to an HCP’s practice, as well as notepads and pens — provided they are branded with company-only and not product-specific branding — that are of minimal value and intended to be used in the context of note-taking during company events.
The IFPMA also provided further clarification regarding gifts of medical utility, such as inhalation devices and mobile apps, items of medical utility that HCPs are not expected to provide patients with, and educational items such as journal subscriptions, memory sticks loaded with educational material and scientific books. Product-specific branding is prohibited for gifts of medical utility, and materials must conform to new limits on reasonable value.
These updates to the Code of Practice came in conjunction with the publication of a new IFPMA Ethos, of which the organization says, “This change aims to shift from a rules-based to a values-based Code.” The changes are important for Pharmaceutical companies because they will require significant changes in promotional activities in order to conform with the new requirements.
We recommend a strategic coordination of protocols be undertaken by compliance, sales, meeting-planning and marketing teams to ensure that all parties conform to this new Code of Practice immediately and completely. The scope of these changes provide an instructive example of why cross-silo coordination within Life Sciences companies and their third-party vendor partners is such a critical component of compliance management today.